Ann: Half Year Accounts, page-3

Agreed, from the report:
If top-line results at the completion of the primary efficacy phase are favorable, Opthea intends to file for marketing approval for OPT-302 in 2026 for the treatment of wet AMD in the US, European Union and other territories.

As described in the Operational update in the Directors Report the Company had US$142 million of cash at December 31, 2022.
Opthea believes that it will be able to fund its operating and research and development expenses through at least the fourth calendar quarter of 2024, including with additional funding expected to be available to Opthea under the DFA. T